SCHEMBL29375394

SCHEMBL29375394

[74As]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1650927 1.00
SCHEMBL29771483 1.00
SCHEMBL4595145 1.00
SCHEMBL15913 1.00
SCHEMBL8949676 1.00
SCHEMBL5141623 0.71
SCHEMBL1917094 0.71
Selenium SCHEMBL420182 0.71
SCHEMBL11347325 0.71
SCHEMBL1188017 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213737-A1 MICROSPHERE AND PREPARATION METHOD THEREOF PLATINUM OPTICS TECHNOLOGY INC. (TW) 2025-07-03 US claimed
EP-4578496-A1 MICROSPHERE AND PREPARATION METHOD THEREOF Platinum Optics Technology Inc. (TW) 2025-07-02 EP claimed
CN-118116504-B Method for predicting adsorption behavior of arsenic on 2:1 clay mineral 江西省科学院微生物研究所(江西省流域生态研究所) 2024-08-27 CN claimed
CN-118116504-A Method for predicting adsorption behavior of arsenic on 2:1 clay mineral 江西省科学院微生物研究所(江西省流域生态研究所) 2024-05-31 CN claimed
US-20230190810-A1 ANTI-CD33 ANTIBODIES AND USES THEREOF FRED HUTCHINSON CANCER CENTER (US) 2023-06-22 US claimed
US-20230144405-A1 HUMAN ANTI-CD33 ANTIBODIES AND USES THEREOF FRED HUTCHINSON CANCER CENTER (US) 2023-05-11 US claimed
EP-4126245-A2 ANTI-CD33 ANTIBODIES AND USES THEREOF Fred Hutchinson Cancer Center (US) 2023-02-08 EP claimed
EP-4126248-A2 HUMAN ANTI-CD33 ANTIBODIES AND USES THEREOF Fred Hutchinson Cancer Center (US) 2023-02-08 EP claimed
CN-115397515-A Human anti-CD 33 antibodies and uses thereof 弗莱德哈钦森癌症中心 2022-11-25 CN claimed
CN-115297932-A anti-CD 33 antibodies and uses thereof 弗莱德哈钦森癌症中心 2022-11-04 CN claimed
CN-110227170-B Radioactive microsphere and preparation method thereof 白金科技股份有限公司 2022-06-14 CN claimed
US-12600801-B2 Single-domain antibodies that bind ROR1 FRED HUTCHINSON CANCER CENTER (US) 2026-04-14 US disclosed
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2026-03-26 US disclosed
US-20260084978-A1 PROCESS FOR PRODUCING ATOMIC QUANTUM CLUSTERS DERIVATIVES NANOGAP SUB NM POWDER S A (ES) 2026-03-26 US disclosed
EP-4709424-A1 LYOPHILIZED PRODUCTS, PHARMACEUTICAL COMPOSITIONS, AND KITS COMPRISING DYE-PEPTIDE CONJUGATES AND DERIVATIVES Integro Theranostics, LLC (US) 2026-03-18 EP disclosed
CN-108440515-B Substituted benzofuranyl and benzoxazolyl compounds and uses thereof 卡尔约药物治疗公司 2022-05-03 CN disclosed
CN-114340690-A Ocular device delivery methods and systems 雷尔生物公司 2022-04-12 CN disclosed
EP-3962498-A1 COMBINATION THERAPIES Memorial Sloan Kettering Cancer Center (US) 2022-03-09 EP disclosed
US-20220054550-A1 COMBINATION THERAPIES MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2022-02-24 US disclosed
CN-114025775-A Combination therapy 纪念斯隆-凯特琳癌症中心 2022-02-08 CN disclosed